A user’s guide to cannabinoid therapies in oncology

Current Oncology

Volumn 23, Issue 6, 2016, Pages 398-406

  Maida, Vincent ^a,b,c   Daeninck, P J ^d,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c William Osler Health System   (Canada)

^d St Boniface Unit   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f NONE   (Canada)

Author keywords

Cannabidiol; Cannabinoids; CBD; Marijuana; Medical cannabis; Pharmaceutical cannabinoids; THC; 9 tetrahydrocannabinol

Indexed keywords

ANTINEOPLASTIC AGENT; CANNABIDIOL; CANNABINOID RECEPTOR; CYTOCHROME P450; DEXANABINOL; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; OPIATE; TEMOZOLOMIDE; TETRAHYDROCANNABINOL;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANOREXIA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG BIOAVAILABILITY; GLIOBLASTOMA; HUMAN; HYPERALGESIA; IMMUNE DEFICIENCY; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYENDOCRINOPATHY; POLYPHARMACY; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 85007037751     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.3487     Document Type: Review

References (94)

1. Pertwee RG, ed. Handbook of Cannabis. Oxford, U.K.: Oxford University Press; 2014.
2. Guy GW, Whittle BA, Robson PJ, eds. The Medicinal Uses of Cannabis and Cannabinoids. London, U.K.: Pharmaceutical Press; 2004.
3. Grotenhermen F, Russo E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York, NY: The Haworth Therapeutic Press; 2002.
4. Devinsky O, Cohen LR, Selig R. Weed: marijuana, medicine and neuroscience: history of the Alfred I. DuPont–Columbia University Award. Neurosurgery 2015;76:357–61.
5. Health Canada. Authorized Licensed Producers for Medical Purposes [Web page]. Ottawa, ON: Health Canada; 2013. [Updated version available at: http://www.hc-sc.gc.ca/dhp​ -mps/marihuana/info/list-eng.php; cited 10 October 2016]
6. Russo EB. Taming thc: potential cannabis synergy and phytocannabinoid–terpenoid entourage effects. Br J Pharmacol 2011;163:1344–64.
7. Maida V. Medical cannabis in the palliation of malignant wounds—a case report. J Pain Symptom Manage 2016;
8. Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T. Programming of neural cells by (endo) cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci 2014;15:786–801.
9. Maccarrone M, Bab I, Biro T, et al. Endocannabinoid signaling at the periphery: 50 years after thc. Trends Pharmacol Sci 2015;36:277–96.
10. Pertwee RG, Howlett AC, Abood ME, et al. Cannabinoid receptors and their ligands: beyond cb1 and cb2. Pharmacol Rev 2010;62:588–631.
11. Davis DP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 2016;14:915–22.
12. Benard G, Massa F, Puente N, et al. Mitochondrial cb1 receptors regulate neuronal energy metabolism. Nat Neurosci 2012;15:558–64.
13. Zuardi AW, Crippa JA, Hallak JE, et al. A critical review of the antipsychotic effects of cannabidiol; 30 years of a translational investigation. Curr Pharm 2012;18:5131–40.
14. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals (Basel) 2012;5:529–52.
15. Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. Cannabis tea revisited: a systemic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol 2007;113:85–90.
16. Romano LL, Hazekamp A. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013;1:1–11.
17. Grotenhermen F. Pharmcokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–60.
18. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006;30(suppl 1):S13–18.
19. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10(suppl A):15A–22A.
20. Watanabe K, Yamori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007;80:1415–19.
21. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible of cannabidiol by human liver microsomes. Life Sci 2011;89:165–70.
22. Stout SM, Cimino NM. Exogenous cannabinoids as sub-strates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014;46:86–95.
23. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 2009;85:273–6.
24. Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 2016;55:1353–68.
25. Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009;43:1347–53.
26. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 2012;30:880–7.
27. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005;2:18.
28. Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol 2016;23:S8–14.
29. McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008;103:1100–9.
30. Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol 2008;26:2214–15.
31. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. Respirology 2014;19:655–62.
32. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 2015;313:2491–3.
33. Perrier L. Why I chose to use cannabis. Curr Oncol 2016;23:S7.
34. Lynch M, Campbell F. Cannabinoids for treatment of chronic, non-cancer pain: a systematic review of randomised trials. Brit J Clin Pharmacol 2011;72:735–44.
35. Lynch M, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials J Neuroimmune Pharmcol 2015;10:293–301.
36. Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids a safe and effective treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13–16.
37. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21(suppl):320S–6S.
38. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53:769–75.
39. Beaulieu P, Boulanger A, Desroches J, Clark AJ. Medical cannabis: considerations for the anesthesiologist and pain physician. Can J Anaesth 2016;63:608–24.
40. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of thc:cbd extract and thc extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167–79.
41. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-​ dose trial. J Pain 2012;13:438–49.
42. Moulin D, Boulanger A, Clark AJ, et al. on behalf of the Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014;19:328–35.
43. Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain 2015;16:1221–32.
44. Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-​ tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795–7.
45. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16–21.
46. Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sa-tiva on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008;17:431–43.
47. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahydro-cannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979;91:819–24.
48. 9 -tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. J Cannabis Ther 2001;1:26–56.
49. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 2011;163:1411–22.
50. Priestman TJ, Priestman SG. An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol 1984;35:265–6.
51. Côté M, Trudel M, Wang C, Fortin A. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol 2016;125;317–24.
52. Elliott DA, Nabavizadeh N, Romer JL, Chen Y, Holland JM. Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy. Support Care Cancer 2016;24:3517–24.
53. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567–73.
54. Strasser F, Luftner D, Possinger K, et al. on behalf of the Cannabis-In-Cachexia-Study-Group. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannab-inol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase iii, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394–400.
55. Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011;22:2086–93.
56. + marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 2005;181:170–8.
57. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997;12:913–19.
58. Munson AE, Harris LA, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602.
59. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006;66:6748–55.
60. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008;68:339–42.
61. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett 2009;285:6–12.
62. Velasco G, Sanchez C, Guzman M. Anticancer mechanisms of cannabinoids. Curr Oncol 2016;23:S23–32.
63. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95:197–203.
64. Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/canna-binoid combination triggers autophagy in pancreatic cancer cells through a ros-mediated mechanism. Cell Death Dis 2011;2:e152.
65. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90–103.
66. Miyato H, Kitayama J, Yamashita H, et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res 2009;155:40–7.
67. Preet A, Qamri Z, Nasser MW, et al. Cannabinoid receptors, cb1 and cb2, as novel targets for inhibition of non–small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 2010;4:65–75.
68. Gustafsson SB, Lindgren T, Jonsson M, Jacobsson SO. Cannabinoid receptor–independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2009;63:691–701.
69. Preet A, Ganju RK, Groopman JE. Delta-9-tetrahydrocannab-inol inhibits epithelial growth factor–induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008;27:339–46.
70. Health Canada. Consumer Information—Cannabis [Web page]. Ottawa, ON: Health Canada; 2016. [Available at: http:// www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/ info/cons-eng.pdf; cited 10 October 2016]
71. College of Family Physicians of Canada (cfpc). Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada. Mississauga, ON: cfpc; 2014.
72. Canadian Medical Protective Association (cmpa). Medical marijuana: considerations for Canadian doctors [Web ar-ticle]. Ottawa, ON: cmpa; 2016. [Available at: https://www. cmpa-acpm.ca/en/legal-and-regulatory-proceedings/-/ asset_publisher/a9unChEc2NP9/content/medical-mari​ juana-new-regulations-new-college-guidance-for-canadian-​ doctors; cited 2 October 2016]
73. Solowij N, Broyd SJ, van Hell HH, Hazekamp A. A protocol for the delivery of cannabidiol (cbd) and combined cbd and Δ9-tetrahydrocannabinol (thc) by vaporisation. BMC Pharmacol Toxicol 2014;15:58.
74. Reus GZ, Stringari RB, Ribeiro KF, et al. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatr 2011;23:241–8.
75. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367:3364–78.
76. 1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 2014;171:636–45.
77. Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010;159:122–8.
78. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–8.
79. Zwarenstein M, Goldman J Reeves. Interprofessional collaboration: effects of practice-based interventions on professional practice and outcomes. Cochrane Database Syst Rev 2009;:CD000072.
80. Reeves S, Perrier L, Goldman J, Freeth D, Zwarenstein M. Interprofessional education; effects on professional practice and healthcare outcomes (update). Cochrane Database Syst Rev 2013;:CD002213.
81. Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA. Medical marijuana and the developing role of the pharmacist. Am J Health-Syst Pharm 2007;64:1037–44.
82. Isaac S, Saini B, Charr BB. The role of medicinal cannabis in clinical therapy: pharmacists perspectives. Plos One 2016;11:e0155113.
83. Sznitman SR, Goldberg V, Sheinman-Yuffe H, Fletcher E, Bar-Sela G. Storage and disposal of medical cannabis among patients with cancer: assessing the risk of diversion and unintentional digestion. Cancer 2016;122:3363–70.
84. Kuo YF, Raji MA, Chen NW, Hasan H, Goodwin JS. Trends in opioid prescriptions among Part D Medicare recipients from 2007 to 2012. Am J Med 2016;129:221.e21–30.
85. Mehendale AW, Goldman MP, Mehendale RP. Opioid overuse syndrome (oops): the story of opioids, Prometheus unbound. J Opioid Manag 2013;9:421–38.
86. Carmona-Bayonas A, Jiminez-Fonseca P, Castanon E, et al. Chronic opioid therapy in long term cancer survivors. Clin Transl Oncol 2016;:[Epub ahead of print].
87. Owens MR, Simmons B, Gibson PS, Weeks D. A longitudinal study of pain in hospice and pre-hospice patients. Am J Hospice Palliat Care 2001;18:124–8.
88. Sacerdote P. Opioids and the immune system. Palliat Med 2006;20(suppl 1):s9–15.
89. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 2008;6:119–24.
90. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014;174:1668–73.
91. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacology 1994;2:244–68.
92. Nutt DJ, King LA, Phillips LD on behalf of the Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010;376:1558–65.
93. Collen M. Prescribing cannabis for harm reduction [editorial]. Harm Reduct J 2012;9:1.
94. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood) 2016;35:1230–6.